Dynamic Technology Lab Private Ltd Purchases New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Dynamic Technology Lab Private Ltd purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 23,578 shares of the company’s stock, valued at approximately $530,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC lifted its position in shares of Nurix Therapeutics by 365.0% during the second quarter. SG Americas Securities LLC now owns 103,199 shares of the company’s stock worth $2,154,000 after purchasing an additional 81,005 shares in the last quarter. Renaissance Technologies LLC boosted its position in Nurix Therapeutics by 80.7% in the 2nd quarter. Renaissance Technologies LLC now owns 324,000 shares of the company’s stock valued at $6,762,000 after buying an additional 144,700 shares during the last quarter. TD Asset Management Inc purchased a new stake in shares of Nurix Therapeutics during the second quarter worth about $593,000. Bank of New York Mellon Corp increased its position in shares of Nurix Therapeutics by 31.4% during the second quarter. Bank of New York Mellon Corp now owns 209,136 shares of the company’s stock worth $4,365,000 after acquiring an additional 49,918 shares during the last quarter. Finally, Candriam S.C.A. boosted its holdings in Nurix Therapeutics by 30.5% in the second quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after purchasing an additional 272,136 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NRIX. Stephens restated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Monday, October 14th. Jefferies Financial Group initiated coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $41.00 price target for the company. Oppenheimer raised their price objective on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Royal Bank of Canada cut their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Finally, HC Wainwright lifted their price target on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $29.40.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $22.11 on Friday. Nurix Therapeutics, Inc. has a 12 month low of $5.95 and a 12 month high of $29.56. The stock has a fifty day moving average price of $24.02 and a 200 day moving average price of $21.75. The company has a market cap of $1.57 billion, a P/E ratio of -7.60 and a beta of 2.20.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67). The business had revenue of $12.59 million for the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. As a group, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Christine Ring sold 5,760 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $22.23, for a total value of $128,044.80. Following the sale, the insider now directly owns 24,592 shares in the company, valued at $546,680.16. This trade represents a 18.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,368 shares of Nurix Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $57,542.40. Following the sale, the chief financial officer now directly owns 37,270 shares in the company, valued at $905,661. The trade was a 5.97 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,451 shares of company stock worth $663,160. 7.20% of the stock is owned by company insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.